Three doses of p67C antigen generated stronger immune responses than two doses. Antibody titres and CD4+ T-cell proliferation correlated with protection against East Coast fever. The number of doses could not be reduced from three to two without compromising the protection.
To support research on the biology of T. parva and the identification of additional candidate vaccine antigens, this article reports on the sporozoite proteome as defined by LC–MS/MS analysis.
Green Mountain Antibodies has signed an agreement with the International Livestock Research Institute (ILRI) of Nairobi, Kenya to produce and distribute monoclonal antibodies that detect infectious disease markers in cattle.
There is inadequate herd and community level information on the impact of CBPP and its control by vaccination to allow adequate allocation of resources for CBPP control in affected ecosystems of Kenya. A study was designed in Narok district to provide this crucial information for the Maasai ecosystem.
There is a great deal of similarity in the immunopathology, genomics and biology of T. parva and T. annulata. Similar protective immune responses are directed against the sporozoite and schizont stages of the parasites, and it is remarkable that many candidate sporozoite and schizont antigens are also so similar to each other. Hence, advances in development of subunit vaccines against one parasite species are likely to be readily applicable to the other.
The ECF consortium is aiming at producing a vaccine that would trigger both an antibody response and a T cell dependent response. Thanks to the whole genome sequence of Theileria parva and its annotation, we have short listed hundreds of antigen candidates, but the number of antigen candidate that can be tested in cattle is limited. How do we narrow down the list of candidates to a handful that can be studied rigorously in live experiments?
The recent meeting of the East Coast fever consortium, which brings together experts in immunology, parasitology and genomics from three continents (ILRI, Edinburgh, Antwerp, IGS, as well as the organization that produces the infection and treatment method (ITM) vaccine, provided a venue to discuss a way forward.